Injections vs tablets
Compare injections with tablets and capsules in plain English, including how assessment, support and the way prices are shown can differ.
Compare injections and tablets from the right starting point
Injection comparisons usually focus on dose changes, follow-up and specialist provider tables. Tablet comparisons depend more on medicine name, pack size, access type and whether prices can be compared fairly.
Injection comparison at a glance
Best when you want to compare medicine choice, dose steps, follow-up and which providers have enough checked detail to review.
- Providers in view
- 74
- Details checked
- 709
- Medicines currently covered
- 2
- Last checked
- 29 Apr 2026
You can compare 709 injection checks from 74 providers here. For medicine-specific dose and provider tables, continue to Wego Compare or Jaro Compare.
Tablet and capsule comparison at a glance
Best when you need to compare medicine identity, pack size, pharmacy access and whether the public price can be lined up fairly with another provider.
- Providers in view
- 17
- Details checked
- 39
- Medicines currently covered
- 5
- Last checked
- Date pending
Tablet options appear here only when the medicine, pack size, access type and checked date are clear enough to compare fairly. Current details can still change.
Injections and tablets solve different comparison problems
Short version: injections are usually compared by medicine, dose journey and follow-up. Tablets and capsules are usually compared by active ingredient, strength, pack size, access route and pharmacy or prescriber checks.
Best next step: use injection pages for Mounjaro, Wegovy and Saxenda. Use the tablet page for Orlistat, Xenical, Alli, Orlos and Mysimba.
Best for dose-led comparison
Injections, especially Mounjaro and Wegovy, where dose changes and follow-up matter.
Best for pack-led comparison
Tablets and capsules, where strength, pack size and access route shape the comparison.
Best for access questions
NHS/private and provider pages, where the question is about how care is arranged.
Injections: pros and cons to compare
- Useful when comparing Mounjaro, Wegovy or Saxenda pathways.
- Dose changes and follow-up are central.
- Detailed provider tables should be medicine-specific.
Tablets: pros and cons to compare
- Useful when comparing Orlistat-family options or Mysimba.
- Pack size and access route matter more than they first appear.
- Some listings are not comparable if pack or price basis is unclear.
Which route should you open next?
Mounjaro detail
Use Jaro Compare for provider and dose tables.
Wegovy detail
Use Wego Compare for provider and dose tables.
Tablet comparison
Use the tablet page for pack, access and provider checks.
Access decision
Use NHS vs private when the main question is route to care.
Compare injections
Mounjaro, Wegovy and Saxenda
Use the injections hub for medicine and provider-route comparison.
Compare tablets
Orlistat, Xenical, Alli, Orlos and Mysimba
Use the tablet hub for pack, access and provider comparison.
Compare access
NHS, private and provider types
Use the access comparison when the question is how care is arranged.
Common questions
Are injections stronger than tablets?
That is not a safe universal answer. They are different treatment routes with different eligibility, monitoring and suitability questions.
Why are tablet pages more pack-focused?
Because tablet listings can differ by strength, capsule count, price basis and access route. A fair comparison needs those details.
Where do provider tables belong?
Detailed Mounjaro and Wegovy provider tables belong on the specialist sites. Tablet provider comparison is handled here.
Source notes
These notes explain the basis for the page in plain English: what was checked, when it was checked and where the information came from.
Mysimba Prescribing Information
The Mysimba Summary of Product Characteristics was reviewed for medicine identity and prescribing-information context.
Source: eMC: Mysimba 8 mg/90 mg prolonged-release tablets SmPC
Reviewed for tablet identity context where Mysimba is named as one of the examples.
Orlistat Tablet Context
NHS medicines information was reviewed for orlistat background.
Source: NHS medicines: Orlistat
Used to support public explanation of tablet differences and why pack-aware comparison matters.
Glp1 Safety And Prescription Context
GOV.UK/MHRA patient information was reviewed for GLP-1 medicine safety and prescription-only context.
Source: GOV.UK: GLP-1 medicines for weight loss and diabetes
Reviewed for cautious wording around regulated supply, assessment and side-effect support on injection routes.
Nhs Obesity Treatment Context
NHS guidance was reviewed for broad obesity treatment pathway context.
Source: NHS: Treatment for obesity
Reviewed to explain that treatment pathways can differ and should not be reduced to a simple price comparison.
Nice Weight Management Guidance
NICE guidance was reviewed for broad UK overweight and obesity management context.
Source: NICE NG246: Overweight and obesity management
Reviewed for cautious general guidance language rather than medicine-specific recommendations.
Important information
This website is an informational comparison hub. It does not prescribe, supply or sell prescription-only medicines. Suitability depends on a regulated clinical assessment.
Some links may be affiliate or commercial links. Commercial relationships must not change the way safety, eligibility, checked details or editorial context are presented.